Synlait swings to NZ$4.8m NPAT as net debt drops NZ$167m

What changed

Synlait returned to profitability on nearly every headline line. Revenue rose 40.4% to NZ$916.8m, EBITDA rose 216.9% to NZ$63.1m, and the group swung from a NZ$94.9m pre-tax loss to a NZ$7.5m pre-tax profit. NPAT was NZ$4.8m versus a NZ$96.2m loss. Operating cash flow remained a NZ$12.0m outflow but was NZ$86.1m better than HY24. Gross borrowings fell 25.2% to NZ$440.9m and cash rose to NZ$49.0m, cutting net debt to about NZ$391.9m from NZ$559.3m. By segment, Synlait (the core) generated NZ$778.3m of revenue and NZ$0.6m of segment profit (near break-even), while Dairyworks contributed NZ$138.4m of revenue and NZ$4.2m of profit, meaning the smaller Dairyworks unit is currently doing the heavy lifting at the earnings line.

What matters

• Leverage has materially de-risked. Net debt/EBITDA fell to 6.2x from 28.1x, and gross debt is down NZ$148.9m year on year. This is the single most consequential change and reflects the balance-sheet reset flagged at FY24.
• Core Synlait segment earnings are only just above zero. A NZ$0.6m segment result on NZ$778.3m of revenue implies roughly a 0.1% margin. The "return to profitability" headline is accurate, but the operating base of the core business is still very thin.
• Cash is not yet following the P&L. Operating cash flow was still negative NZ$12.0m, and pre-lease free cash flow was a NZ$23.4m outflow. The NZ$18.5m rise in cash was funded by financing activity rather than by the business itself.

Expectations

HY25 EBITDA of NZ$63.1m was described by management as "just above" the January 2025 guidance range, but the numeric range was not disclosed in the supplied excerpt, so the beat cannot be sized. No forward targets were supplied in the release extract. On shape, HY24 represented only 39.9% of FY24 revenue, indicating a traditionally second-half-weighted top line, though FY24's EBITDA pattern is too distorted by losses to read as a useful seasonal template. Annualising HY25 revenue gives NZ$1.83b, 12.0% above FY24's NZ$1.64b, but whether earnings scale proportionally into 2H is not supported by the release.

Quality of result

The earnings recovery looks partially durable and partially timing/mix-driven. Pre-tax profit is the cleaner operating read here — the 35.9% effective tax rate in HY25 versus a tax benefit in HY24 (when discontinued operations were also present) distorts NPAT comparability. Positives: inventory days fell from 88.2 to 68.9, suggesting better stock turn, and gross borrowings were materially reduced. Concerns: cash conversion, while vastly improved from HY24's OCF/EBITDA of -493%, is still negative at -19.1%; receivable days lengthened from 30.5 to 36.1; and the core Synlait segment is barely above break-even despite a 19.4% revenue uplift in that segment, so operating leverage has not yet shown through meaningfully. No separately disclosed non-recurring items were identified, and no formal non-GAAP bridge from EBITDA to NPAT was provided.

Unresolved

• The January 2025 EBITDA guidance range is not visible in the supplied excerpts, so the scale of the beat cannot be quantified.
• Trade payables are not disclosed, so a complete operating working capital bridge cannot be built — the OCF improvement may partly reflect payables timing.
• No segment-level commentary on margin drivers (milk price, product mix, customer wins/losses) is supplied, so it is not clear why Synlait-segment margin is so thin on strong revenue growth.
• There is no explicit FY25 earnings or leverage target, and no dividend has been declared, leaving capital allocation policy post-reset unclarified.
• Customer concentration (notably around the disclosed strategic review context) is not quantified in the supplied materials.

This briefing cannot assess the terms or likelihood of any further balance-sheet or strategic transaction, the undisclosed EBITDA guidance range, or 2H25 trading conditions.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.